Stockscreener 앱 받기
5.58
18.54%
-1.27
시간 외 거래:
5.75
0.17
+3.05%
Protara Therapeutics Inc 주식(TARA)의 최신 뉴스
Protara Therapeutics: Stock Offer Takes the Spotlight - StocksToTrade
Protara Prices $75 Mln Offering To Advance TARA-002 And Broader Pipeline - Nasdaq
Biotech co Protara slides on $75 mln share sale - TradingView
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN
Protara Therapeutics Shares Sink 16% After $75 Mln Public Offering - Nasdaq
Protara Therapeutics (Nasdaq: TARA) prices 13,043,479-share, $75M public deal - Stock Titan
Protara Therapeutics (TARA) Launches $75M Public Offering - GuruFocus
Protara Therapeutics Prices $75 Million Share Offering - marketscreener.com
Will Protara Therapeutics Inc. (1KPA) stock benefit from sector leadershipJuly 2025 Price Swings & Accurate Trade Setup Notifications - Newser
TARA Stock Offering Priced at Lower End of Target Range - GuruFocus
Protara Therapeutics prices $75 million public offering - Investing.com
Protara Announces Pricing of $75 Million Public Offering - The Manila Times
Protara Therapeutics prices $75 million public offering By Investing.com - Investing.com UK
Protara prices public offering of 13.04 million shares at $5.75 each - marketscreener.com
Key Managers Announced for TARA Offering - GuruFocus
Protara Therapeutics Launches Offering of Securities - marketscreener.com
Protara announces proposed public offering - MSN
Protara Therapeutics stock tumbles after $75M public offering By Investing.com - Investing.com South Africa
Protara Therapeutics stock tumbles after $75M public offering - Investing.com
Protara Therapeutics announces $75 million public offering By Investing.com - Investing.com South Africa
Protara Announces Proposed Public Offering - The Manila Times
Protara Therapeutics Announces $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Protara Therapeutics (Nasdaq: TARA) starts $75M stock and pre-funded warrant sale - Stock Titan
Protara Therapeutics (NASDAQ:TARA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients - MarketScreener
Protara Therapeutics: End Of 2025 Proving Eventful Indeed (NASDAQ:TARA) - Seeking Alpha
Why Protara Therapeutics Inc. (1KPA) stock is listed among top recommendationsEarnings Overview Report & Daily Stock Trend Reports - Newser
Protara Therapeutics (NASDAQ:TARA) Receives Buy Rating from HC Wainwright - Defense World
HC Wainwright & Co. Reiterates Protara Therapeutics (TARA) Buy Recommendation - Nasdaq
TARA: HC Wainwright & Co. Reiterates 'Buy' Rating with $23 Targe - GuruFocus
TARA: TARA-002 shows 69% six-month CR and strong safety in BCG naive NMIBC, advancing to registrational trial - TradingView
Protara Reports Updated Interim Phase 2 Data Of TARA-002 In Non-muscle Invasive Bladder Cancer - RTTNews
Protara Therapeutics reports positive results from bladder cancer study - Seeking Alpha
Protara Therapeutics, Inc. (TARA) Jumps 14.6% in Pre-market Trading: After Positive Data Release - Stocks Telegraph
Protara Therapeutics (TARA) Reveals Promising Data from Phase 2 Bladder Cancer Trial - GuruFocus
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial - TradingView
Protara Therapeutics Announces Updated Interim Data from - GlobeNewswire
Is Protara Therapeutics Inc. (1KPA) stock attractive for dividend growthTrade Entry Summary & Safe Capital Allocation Plans - Newser
Adversity is less terrifying than hope: Protara Therapeutics Inc (TARA) - Setenews
Will Protara Therapeutics Inc. (1KPA) stock sustain uptrend momentum2025 EndofYear Setup & Risk Adjusted Swing Trade Ideas - Newser
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close - Nasdaq
Protara to host conference call on TARA-002 bladder cancer trial data - Investing.com Nigeria
Protara Therapeutics to Host Conference Call on December 3 to Discuss Interim Phase 2 Data for TARA-002 in Bladder Cancer - Quiver Quantitative
Protara Therapeutics to Host Conference Call and Webcast to - GlobeNewswire
Is Protara Therapeutics Inc. stock trading near support levelsJuly 2025 Sentiment & Stock Portfolio Risk Control - BỘ NỘI VỤ
Why Protara Therapeutics Inc. stock could outperform in 2025Earnings Miss & Short-Term Swing Trade Alerts - BỘ NỘI VỤ
This Insider Bought 20000.0 Shares In Protara Therapeutics Inc (TARA) - fostersleader.com
HC Wainwright Has Positive Outlook for TARA Q4 Earnings - MarketBeat
HC Wainwright Has Positive Forecast for TARA Q4 Earnings - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Brokers Set Expectations for TARA Q2 Earnings - Defense World
Protara sees Chugai blue sky in LMs as phase II data strong - BioWorld MedTech
What analysts say about Protara Therapeutics Inc stockBullish Engulfing Patterns & Low Risk Trading Portfolio - earlytimes.in
Insiders Buying Protara Therapeutics Might Wish They Invested More, Stock Gains 30% - Yahoo Finance
Revenue per share of Protara Therapeutics, Inc. – HAM:1KPA - TradingView
Will Protara Therapeutics Inc. (1KPA) stock maintain strong growthWeekly Volume Report & Target Return Focused Picks - newser.com
Chart based analysis of Protara Therapeutics Inc. trendsJuly 2025 PostEarnings & AI Based Buy/Sell Signal Reports - newser.com
Protara Therapeutics (TARA) Receives a Buy from TD Cowen - The Globe and Mail
Is Protara Therapeutics Inc. stock oversold or undervaluedDividend Hike & Intraday High Probability Alerts - newser.com
Protara stock rises after H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Canada
1.44%
0.91%
자본화:
|
볼륨(24시간):